Microbiome–Nutrition Interactions in Early Life and Their Association With Childhood Systolic Blood Pressure
February 17, 2026
Brand Name :
Myochrysine
Synonyms :
sodium aurothiomalate
Class :
Disease-Modifying Antirheumatic Drug, Gold Compounds
Dosage Forms & Strengths
Injectable solution
25mg/ml
50mg/ml
Administer dose of 10 mg intramuscularly in first week and 25 mg in next week, then 25 to 50 mg intramuscularly every week for 20 weeks
Dosage Forms & Strengths
Injectable solution
25mg/ml
50mg/ml
Administer dose of 10 mg intramuscularly in first week, then 1 mg/kg intramuscularly every week
Dose should not be more than 50 mg
Refer to adult dosing
may have an increased immunosuppressive effect when combined with disease-modifying antirheumatic drugs (DMARDS)
may have an increased immunosuppressive effect when combined with disease-modifying antirheumatic drugs
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
Actions and Spectrum
Sodium aurothiomalate has anti-inflammatory properties that help to reduce the signs and symptoms of rheumatoid arthritis.
It inhibits inflammatory processes and cytokine production, thereby suppressing the immune response involved in the pathogenesis of rheumatoid arthritis.
Frequency defined
>10%
Stomatitis
Proteinuria
Pruritis & rash
1-10%
Thrombocytopenia
Leukopenia
Frequency not defined
Exfoliative dermatitis
Nephropathy
Agranulocytosis
Aplastic anemia
Enterocolitis
Liver failure
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: C
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
Sodium aurothiomalate may affect the production and release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukins.
Modulating these cytokines can help regulate the immune response and reduce inflammation in rheumatoid arthritis.
Pharmacodynamics
Sodium aurothiomalate has been associated with the inhibition of DNA synthesis.
This effect may contribute to the suppression of immune cell proliferation and, consequently, the modulation of the immune response.
Pharmacokinetics
Absorption
Sodium aurothiomalate administered via intramuscular injection. The absorption process involves the drug entering the bloodstream from the injection site.
Distribution
Sodium aurothiomalate is distributed throughout the body.
Metabolism
Sodium aurothiomalate undergoes limited metabolism in the body.
Elimination and excretion
Excretion of sodium aurothiomalate occurs through the kidneys.
Administration
Sodium aurothiomalate is administered by intramuscular injection.
Patient information leaflet
Generic Name: sodium aurothiomalate
Why do we use sodium aurothiomalate?
Sodium aurothiomalate is used as a treatment for rheumatoid arthritis.
Sodium aurothiomalate is indicated to modify the course of rheumatoid arthritis by influencing the underlying autoimmune and inflammatory processes.